ProKidney’s stock was the biggest gainer and most actively traded on Tuesday following “very intriguing” news regarding the biotech’s CKD and diabetes treatment.
Source link
ProKidney’s stock rockets on ‘intriguing’ news, but analyst doesn’t recommend buying
Previous ArticleUniCredit doubles its equity stake in Commerzbank to 20%
Related Posts
Add A Comment